Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis Recently, incretin-related agents have been reported to attenuate insulin resistance in animal models, although the underlying mechanisms remain unclear. In this study, we investigated whether anagliptin, the dipeptidyl peptidase 4 (DPP-4) inhibitor, attenuates skeletal muscle insulin resistance through endothelial nitric oxide synthase (eNOS) activation in the endothelial cells. We used endothelium-specific Irs2-knockout (ETIrs2KO) mice, which show skeletal muscle insulin resistance resulting from a reduction of insulin-induced skeletal muscle capillary recruitment as a consequence of impaired eNOS activation.Methods In vivo, 8-week-old male ETIrs2KO mice were fed regular chow with or without 0.3% (wt/wt) DPP-4 inhibitor for 8 weeks to assess capillary recruitment and glucose uptake by the skeletal muscle. In vitro, human coronary arterial endothelial cells (HCAECs) were used to explore the effect of glucagon-like peptide 1 (GLP-1) on eNOS activity.Results Treatment with anagliptin ameliorated the impaired insulin-induced increase in capillary blood volume, interstitial insulin concentration and skeletal muscle glucose uptake in ETIrs2KO mice. This improvement in insulin-induced glucose uptake was almost completely abrogated by the GLP-1 receptor (GLP-1R) antagonist exendin-(9-39). Moreover, the increase in capillary blood volume with anagliptin treatment was also completely inhibited by the NOS inhibitor. GLP-1 augmented eNOS phosphorylation in HCAECs, with the effect completely disappearing after exposure to the protein kinase A (PKA) inhibitor H89. These data suggest that anagliptin treatment enhances insulin-induced capillary recruitment and interstitial insulin concentrations, resulting in improved skeletal muscle glucose uptake by directly acting on the endothelial cells via NO- and GLP-1-dependent mechanisms in vivo.Conclusions/interpretation Anagliptin may be a promising agent to ameliorate skeletal muscle insulin resistance in obese patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The notable advantage for muscle preservation seems to be the use of glucagon-like peptide-1 (GLP-1) receptor agonists34,35 and dipeptidyl peptidase-4 inhibitors (DPP-4i),36–38 which not only minimally affects muscle mass loss but also stimulates muscle contraction and aid in muscle recovery.”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Vincent, M. A., Clerk, L. H., Lindner, J. R., Klibanov, A. L., Clark, M. G., Rattigan, S., & Barrett, E. J. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1418 · Cited by 438
Kubota, T., Kubota, N., Kumagai, H., Yamaguchi, S., Kozono, H., Takahashi, T., Inoue, M., Itoh, S., Takamoto, I., Sasako, T., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.018 · Cited by 435
Self-citation
Research works printed but not linked: 1
- Sunami Y, Sesoko S, Kaku K (2012) Pharmacokinetics and pharmacodynamics of single and multiple doses of anagliptin, a novel inhibitor of dipeptidyl peptidase-4. Jpn Pharmacol Ther 40:847–858 [article in Japanese]
Cited by
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
Jiang, T., Jiang, D., Zhang, L., Ding, M., & Zhou, H. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.01.006 · Cited by 52
Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions
Wang, T., Zhou, D., & Hong, Z. (2025) · MedComm · doi:10.1002/mco2.70030 · Cited by 46
Kalhotra, P., Chittepu, V. C. S. R., Osorio-Revilla, G. I., & Gallardo‐Velázquez, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051228 · Cited by 44
Li, Z., Zhu, Y., Li, C., Tang, Y., Jiang, Z., Yang, M., Ni, C., Li, D., Chen, L., & Niu, W. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0836-x · Cited by 39
Metadata
- Authors
- Sato, H., Kubota, N., Kubota, T., Takamoto, I., Iwayama, K., Tokuyama, K., Moroi, M., Sugi, K., Nakaya, K., Goto, M., Jomori, T., & Kadowaki, T.
- Affiliations
- The University of Tokyo (JP)
- RIKEN Center for Integrative Medical Sciences (JP)
- Toho University Ohashi Medical Center (JP)
- University of Tsukuba (JP)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Kubota, Naoto
- Kadowaki, Takashi
- ORCID
- Venue
- Diabetologia
- Published
- 2016-08-15
- Volume
- 59
- Issue
- 11
- Pages
- 2426-2434
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2512856880
- Cited by
- 19
- References
- 40
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 3
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (20229008, 18209033, 19591037, 16209030, 21390279)
- Japan Society for the Promotion of Science (15H04847, 26000012)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- anagliptin, DPP-4 inhibitors, skeletal muscle insulin resistance, endothelial nitric oxide synthase, nitric oxide, endothelial cells, capillary recruitment, glucagon-like peptide-1, GLP-1 receptor, protein kinase A, type 2 diabetes, obesity
- MeSH terms
- Animals, Insulin, Insulin Resistance, Male, Nitrogen Oxides, Pyrimidines, Muscle, Skeletal, Dipeptidyl Peptidase 4, Endothelial Cells, Mice, Nitric Oxide Synthase Type III, Tandem Mass Spectrometry, Dipeptidyl-Peptidase IV Inhibitors, Insulin Receptor Substrate Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice. https://app.cochat.ai/papers/10.1007/s00125-016-4071-8
- The paper
- Sato, H., Kubota, N., Kubota, T., Takamoto, I., Iwayama, K., Tokuyama, K., Moroi, M., Sugi, K., Nakaya, K., Goto, M., Jomori, T., & Kadowaki, T. (2016). Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice. Diabetologia. https://doi.org/10.1007/s00125-016-4071-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.